Results of late-breaking developments from the POSEIDON Phase III trial revealed improved overall survival with a limited course of five cycles of tremelimumab added to durvalumab plus platinum chemotherapy.
Friday
December
01
Top Stories
Sponsored
Case-Based Discussion on Management of Select Adverse Events | Part 1: Overview of a Treatment Option for HR+/HER2- Metastatic Breast Cancer
Click video to watch this presentation by Dr Yuan Yuan, MD, PhD, a breast medical oncologist and physician-scientist who specializes in triple-negative breast cancer and breast cancer immunotherapy. Dr Yuan completed her medical degree in China and a fellowship in hematology and oncology at NYU. Additionally, she holds a PhD in biochemistry and molecular biology from the University of California, Riverside.
Sponsored
Case-Based Discussion on Management of Select Adverse Events | Part 3: Case Presentation #2 and Questions
Watch Dr Yuan Yuan, MD, PhD, walk through a hypothetical patient case centered on potential management strategies for grade 2 diarrhea and grade 4 neutropenia that may be experienced with a treatment option for patients with certain types of metastatic breast cancer. Follow along with the case-based questions in the video by answering the questions below to assess what you learned!
Trending
Breast Cancer
Lung Cancer
Start your day with an email
that tells you what’s happening
and why it matters.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->